Edwards strong Q3 propels shares to 10-year high
This article was originally published in Clinica
On the eve of posting strong third-quarter financials, shares in Edwards Lifesciences leapt to their highest ever value on the NYSE. On October 20, the day before announcing its Q3results, Edwards’ shares peaked at $72.45 each, signalling its best pricing in nearly ten years as a publicly-listed firm.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals